The testosterone gel marketplace just got hotter with the announcement that Actavis has filed for FDA approval for its generic version of Androgel.
Whilst the true competition lies in the patient application procedure it is clear that with additional leading pharma companies entering the market that credibility in the drug is becoming more and more accepted.
See our earlier article for a comparison between Androforte and Androgel to see the benefits of applying a cream direct to the scrotum (Androforte) and applying an alchohol based gel to the chest (Androgel)
PARSIPPANY, N.J., April 1, 2013 /PRNewswire/ — Actavis, Inc. (ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Testosterone Gel, 1.62%. Actavis’s ANDA product is a generic version of AbbVie Inc.’s AndroGel ®Â 1.62%, which is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
